Core Insights - AbbVie is increasing its R&D investments to support long-term growth across various therapeutic areas, including immunology, oncology, and neuroscience [1] Pipeline Developments - Key pipeline assets include label expansion studies for Rinvoq and new candidates like tavapadon and pivekimab sunirine (PVEK), with several candidates in late-stage development or under FDA review [2] - Rinvoq is undergoing label expansions for five additional indications, which could add approximately $2 billion to its peak-year sales, with regulatory submissions expected soon [3] - Tavapadon has been submitted for FDA approval as a treatment for Parkinson's disease, supported by positive data from late-stage studies [4] - PVEK is under FDA review for a rare blood cancer and is also being developed for acute myeloid leukemia [5][6] Acquisition Strategy - AbbVie has executed over 30 M&A transactions since early 2024 to enhance its early-stage pipeline, including the acquisition of Gilgamesh Pharmaceuticals for a drug targeting major depressive disorder [7][8] Competitive Landscape - AbbVie remains a dominant player in the immunology market with blockbuster drugs like Skyrizi, Rinvoq, and Humira, despite facing challenges from competitors like Johnson & Johnson and Eli Lilly [9][11][12] Financial Performance - AbbVie shares have outperformed the industry year-to-date and are trading at a slight discount to the industry average based on the P/E ratio [13][14] - EPS estimates for 2025 and 2026 have shown mixed movements, with some revisions indicating slight increases and others showing declines [16]